Intensive Care Unit Research
The research and data management office of the Intensive Care Unit aims to:
- Promote high quality interdisciplinary research into all aspects of critical illness.
- Encourage a culture of enquiry within the intensive care unit community.
What we do
The Canberra Hospital Intensive Care Research Unit follows Good Clinical Practice guidelines for research and evidenced based practice.
Its dedicated research team, work full-time on a multitude of clinical projects at several levels that include intra unit, intra hospital, university collaborations and pharmaceutical clinical trials.
Research Coordinator & Data Manager
Phone: 02 6244 2552
Fax: 02 6244 3507
- ARISE is a multicentre randomised controlled trial of early goal directed therapy in patients admitted to ED with severe sepsis. Early goal directed therapy is compared to standard care for septic patients including fluids and inotropes.
- BLISS is a sub-study of ARISE investigating the presence of DNA from bacteria in septic patient’s blood. This study is looking at inflammatory and genetic markers of sepsis.
- CLAB study is looking at the incidence of blood stream infection in patients who have had a central venous catheter during their stay in ICU.
- EPO-TBI is a large multi-centre randomised controlled trial of Erythropoietin in patients with moderate to severe traumatic brain injuries.
- HEAT is a study looking at permissive hyperthermia through avoidance of Paracetamol in known or suspected infection in ICU.
- TRANSFUSE is an ICU multicentre trial comparing the use of the freshest blood for transfusion with the current practice of giving the blood that is next to expire.
- POINT PREVALENCE PROGRAM is a project that all ICUs across Australia and New Zealand are encouraged to participate in to investigate work practice in ICU on a set day.
- IMT is a study that aims to determine whether specific exercises for the breathing muscles shortens the time to breathing without a ventilator in patients who are mechanically ventilated for more than 1 week.
- BLING a phase IIb randomised controlled trial of continuous beta-bactrum dosing in critically ill patients.
- DahLia is a randomised double-blind, multi-centre placebo controlled trial of Dexmedetomidine for ventilated patients with agitation and delirium in the Intensive Care Unit.
- GSK IV is an open label trial looking at the use of Intravenous Zanamivir for patients who test positive to Influenza A or B on PCR.
- RECLAIM II is a double blind, double dummy study looking at the use of a group of intravenous antibiotics, Meropenum, Ceftrizidime Avibactum and Metronitozole to treat complicated intra-abdominal infections post operatively.
- TARGET is a double blinded feasibility study looking at hypercaloric vs standard calorie naso-gastric feeding in ICU.